GnRH激动剂对化疗患者卵巢功能保护的meta分析-东南大学学报医学版

GnRH激动剂对化疗患者卵巢功能保护的meta分析

单位：1. 江苏省人民医院妇科, 江苏南京 210009;
2. 东南大学附属中大医院妇产科, 江苏南京 210009

分类号：R730.5

出版年·卷·期（页码）：2018·37·第六期（1049-1054）

摘要：

目的：系统评价促性腺激素释放激素激动剂（gonadotropin-releasing hormone agonist，GnRH-a）对恶性肿瘤患者化疗中卵巢功能的保护作用。方法：通过PubMed、EMBASE、CNKI等数据库，收集国内外关于恶性肿瘤患者行辅助化疗联合GnRH-a治疗的随机对照研究，使用Stata 11.0对资料进行meta分析。结果：与单纯化疗相比，化疗联合GnRH-a对化疗后月经及卵巢排卵功能影响的RR值分别为1.34（95%CI：1.16~1.56）和2.45（95%CI：1.43~4.20），差异有统计学意义（P<0.05）。化疗联合GnRH-a组与单纯化疗组治疗后妊娠率比较，差异无统计学差异（P>0.05）。结论：化疗联合GnRH-a有助于化疗后月经及排卵功能的恢复，并提高患者妊娠率，对卵巢功能有保护作用。该结论需更大样本的随机对照研究加以验证。

Objective:To systematically evaluate the protective effect of gonadotropin-releasing hormone agonist (GnRH-a) on ovarian function in patients with malignant tumor during chemotherapy.Methods:The RCTs were identified to assess the efficacy of GnRH agonist by searching PubMed, EMBASE, CNKI, et al. Stata 11.0 was used for analying data. Results:Administration of GnRH agonists was effective in protecting menstruation and ovulation after chemotherapy[RR=1.34 (95% CI:1.16~1.56) and 2.45 (95% CI:1.43~4.20)] respectively, the difference was statistically significant (P<0.05). Pregnancy rates were not significantly different between the two groups (P>0.05). Conclusion:GnRH agonists seem to be effective in protecting ovaries during chemotherapy, although no significant difference in pregnancy rates was seen. More RCTs are needed to verify this conclusion.

参考文献：

[1] HIGGINS J P,THOMPSON S G,DECKS J J,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560.
[2] BEGG C B,MAZUMDAR M.Operating characteristics of a rank correlation test for publication bias[J].Biometrics,1994,50(4):1088-1101.
[3] GERBER B,Von MINCKWITZ G,STEHLE H,et al.Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study[J].J Clin Oncol,2011,29(17):2334-2341.
[4] Del MASTRO L,BONI L,MICHELOTTI A,et al.Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer:a randomized trial[J].JAMA,2011,306(3):269-276.
[5] WAXMAN J H,AHMED R,SMITH D,et al.Failure to preserve fertility in patients with Hodgkin's disease[J].Cancer Chemoth Pharm,1987,19(2):159-162.
[6] GILANI M M,HASANZADEH M,GHAEMMAGHAMI F,et al.Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy[J].Asia Pac J Clin Oncol,2007,3(2):79-83.
[7] GIUSEPPE L,ATTILIO G,EDOARDO D N,et al.Ovarian function after cancer treatment in young women affected by Hodgkin disease(HD)[J].Hematology,2007,12(2):141-147.
[8] BADAWY A,ELNASHAR A,El-ASHRY M,et al.Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage:prospective randomized study[J].Fertil Steril,2009,91(3):694-697.
[9] MUNSTER P N,MOORE A P,ISMAIL-KHAN R,et al.Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer[J].J Clin Oncology,2012,30(5):533-538.
[10] SVERRISDOTTIR A,NYSTEDT M,JOHANSSON H,et al.Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer:results from a randomized trial[J].Breast Cancer Res Treat,2009,117(3):561-567.
[11] ELGINDY E A,El-HAIEG D O.Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage:a randomized controlled trial[J].Obstet Gynecol,2013,121(1):78-86.
[12] 孙晶波,任云会,李文庆.诺雷德对乳腺癌化疗患者月经复潮影响的临床研究[J].中国伤残医学,2011,19(11):15-16.
[13] 李明毅,黄河,梁颖,等.化疗前应用诺雷德预处理对乳腺癌患者月经复潮的影响[J].中国肿瘤临床,2008,35(16):905-907.
[14] BLUMENFELD Z.The role of GnRH agonist cotreatment in addition to cryopreservation of embryo,oocytes,or ovaries[J].Oncologist.2007,12:1044-1054.
[15] SONG G,GAO H,YUAN Z.Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy inpremenopausal patients with breast cancer:results from a phase Ⅱ randomized trial[J].Med Oncol.2013;30(3):1-8.
[16] DEMEESTERE I,BRICE P,PECATORI F A,et al.No Evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy:final long-term report of a prospective randomized trial[J].J Clin Oncol,2016,34(22):2568-2574.
[17] MOORE H C,UNGER J M,PHILLIPS K A,et al.Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J].N Engl J Med,2015,372(10):923-932.
[18] JADAD A R,MOORE A,CARROLL D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J].Control Clin Trials,1996,17(1):1-12.
[19] IMAI A,SUGIYAMA M,FURUI T,et al.Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage[J].Gynecol Obstet Invest,2007,63:102-106.
[20] BECK-FRUCHTER R,WEISS A,SHALEV E et al.GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy:a review of the clinical data[J].Hum Reprod Update,2008,14(6):553-561.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录